Insulet shows bullish trends with strong growth, favorable Wall Street ratings, and a 3.2:1 reward-risk ratio. Read more on ...

Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system is worn on the body for approximately three days at a time and allows ...

Click here to discover the nuances of Insulet with our detailed analytical report. NasdaqGS:PODD Revenue & Expenses Breakdown as at Mar 2025 Insulet (NasdaqGS:PODD) has rewarded its shareholders ...

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy ...

Insulet stock opened at $270.81 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market cap of $19.02 billion, a P/E ...

Shares of Insulet Co. (NASDAQ:PODD – Get Free Report) have received an average rating of “Moderate Buy” from the seventeen research firms that are currently covering the company, MarketBeat ...

Despite being around for over 30 years, Photoshop has never had a dedicated mobile app -- until now. On Tuesday, Adobe announced that Photoshop is finally coming to mobile, packaging its image ...

CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong demand and adoption of ...